Collaboration combines BioMarin’s expertise in drug development with CAMP4’s platform-based target discovery capabilities ...
TARRYTOWN, NY, USA I October 1, 2024 I Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and ...
WARREN, NJ, USA I October 1, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of ...
OXFORD, UK I October 01, 2024 I Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic ...
CAMBRIDGE, MA, USA I September 30, 2024 I Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 ...
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of ...
PBGENE-HBV is the only drug modality designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV ...
The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled single and multiple ascending dose study in healthy volunteers designed to evaluate safety, tolerability, pharmacokinetics ...
SHANGHAI, China & JERSEY CITY, NJ, USA I September 30, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 ...
UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I 30, 2024 I Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...
PARIS, France I 30, 2024 I Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company leading the way in the ...
PLANEGG-MARTINSRIED, Germany I 30, 2024 I Formycon AG (FSE: FYB, “Formycon”) and its commercialization partner Fresenius Kabi jointly announce that ...